MX2009013926A - Compuestos de etinilindol. - Google Patents

Compuestos de etinilindol.

Info

Publication number
MX2009013926A
MX2009013926A MX2009013926A MX2009013926A MX2009013926A MX 2009013926 A MX2009013926 A MX 2009013926A MX 2009013926 A MX2009013926 A MX 2009013926A MX 2009013926 A MX2009013926 A MX 2009013926A MX 2009013926 A MX2009013926 A MX 2009013926A
Authority
MX
Mexico
Prior art keywords
cyslt
chronic
sinusitis
syndrome
oral
Prior art date
Application number
MX2009013926A
Other languages
English (en)
Inventor
Yoshisuke Nakayama
Takeuchijun
Kazuyuki Ohmoto
Satoshi Itadani
Manabu Fujita
Original Assignee
Ono Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ono Pharmaceutical Co filed Critical Ono Pharmaceutical Co
Publication of MX2009013926A publication Critical patent/MX2009013926A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)

Abstract

Como un compuesto que tienen una actividad oral potente y una actividad antagonista de receptor de cysLT1/cysLT2, el compuesto de la fórmula (I): (ver fórmula I) que exhibe actividad antagonista potente contra el receptor de cysLT1/cysLT2, y tiene efecto duradero aún en caso de administración oral y por lo tanto es útil como un agente oral para evitar y/o tratar una variedad de enfermedades, por ejemplo se desarrollaron enfermedades respiratorias (por ejemplo, asma (asma bronquial, etc.), enfermedades pulmonares obstructivas crónicas (COPD), enfisema pulmonar, bronquitis crónica, neumonía (neumonía intersticial, neumonía eosinofílica, etc.), síndrome respiratorio agudo severo (SARS), síndrome de dolor respiratorio agudo (ARDS), síndrome de apnea, rinitis alérgica, sinusitis (sinusitis aguda, sinusitis crónica, etc.), fibrosis pulmonar, tos (tos crónica, etc.) y similares).
MX2009013926A 2008-12-22 2009-12-17 Compuestos de etinilindol. MX2009013926A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2008325815 2008-12-22

Publications (1)

Publication Number Publication Date
MX2009013926A true MX2009013926A (es) 2010-06-22

Family

ID=42110130

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009013926A MX2009013926A (es) 2008-12-22 2009-12-17 Compuestos de etinilindol.

Country Status (18)

Country Link
US (1) US8115014B2 (es)
EP (1) EP2206698B1 (es)
JP (2) JP5012884B2 (es)
KR (1) KR101464778B1 (es)
CN (1) CN101759628B (es)
AU (1) AU2009250960C1 (es)
BR (1) BRPI0905601A2 (es)
CA (1) CA2688614C (es)
DK (1) DK2206698T3 (es)
ES (1) ES2387185T3 (es)
IL (1) IL202869A (es)
MX (1) MX2009013926A (es)
NZ (1) NZ582208A (es)
PL (1) PL2206698T3 (es)
PT (1) PT2206698E (es)
RU (1) RU2505531C2 (es)
TW (1) TWI469965B (es)
ZA (1) ZA200909096B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103080085B (zh) * 2010-06-21 2014-08-13 小野药品工业株式会社 4,4’-[4-氟-7-({4-[4-(3-氟-2-甲基苯基)丁氧基]苯基}乙炔基)-2-甲基-1h-吲哚-1,3-二基]二丁酸的新晶型
KR101171790B1 (ko) 2010-07-30 2012-08-13 현대자동차주식회사 인출식 자전거 캐리어
PT2658844T (pt) 2010-12-28 2017-01-24 Sanofi Sa Novos derivados de pirimidinas, sua preparação e utilização farmacêutica como inibidores de fosforilação de akt (pkb)
EP2537866A1 (en) * 2011-06-21 2012-12-26 Serumwerk Bernburg AG Hydroxyethyl starch derivatives, method for manufacturing the same and therapeutical uses thereof
CN103893146A (zh) * 2012-12-25 2014-07-02 天津药物研究院 含福多司坦缓释剂型
WO2020079652A1 (en) * 2018-10-17 2020-04-23 Insilico Medicine Hong Kong Limited Kinase inhibitors

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE555319A (es) 1956-03-21 1900-01-01
US3095355A (en) 1961-10-12 1963-06-25 Revlon Aerosol composition
JPH01192476A (ja) 1988-01-25 1989-08-02 Kawasaki Steel Corp 溶接鋼管の製造方法
PT93943A (pt) 1989-05-05 1991-02-08 Searle & Co Processo para a preparacao de composicoes contendo compostos indole-2-carboxilato para tratamento de perturbacoes do snc
US5229413A (en) 1989-05-05 1993-07-20 G. D. Searle & Co. Compositions containing indole-2-carboxylate compounds for treatment of CNS disorders
US5137910A (en) 1989-05-05 1992-08-11 C.D. Searle & Co. Compositions containing indole-2-carboxylate compounds for treatment of CNS disorders
CA2019335C (en) 1989-06-27 2000-08-01 Mitoshi Konno Phenylalkan (en)oic acids
GB9027018D0 (en) * 1990-12-12 1991-01-30 Ici Plc Heterocyclic compounds
WO1994022821A1 (en) 1993-04-05 1994-10-13 Fujisawa Pharmaceutical Co., Ltd. Indole derivatives as testosterone 5 alpha-reductase inhibitors
CA2234239C (en) 1995-10-10 2003-05-20 Matthew F. Brown Indole carbamates as leukotriene antagonists
FR2766824B1 (fr) 1997-07-30 1999-09-10 Adir Nouveaux composes heterocycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
GB9902455D0 (en) 1999-02-05 1999-03-24 Zeneca Ltd Chemical compounds
US6608059B1 (en) 2000-06-27 2003-08-19 Smithkline Beecham Corporation Fatty acid synthase inhibitors
JP2003025362A (ja) 2001-07-18 2003-01-29 Nippon Tokushu Toryo Co Ltd 通気性を有する発泡プラスチック及びその製法
US6867224B2 (en) 2002-03-07 2005-03-15 Warner-Lambert Company Compounds that modulate PPAR activity and methods of preparation
US7125906B2 (en) 2002-04-03 2006-10-24 Astrazeneca Ab Indole derivatives having anti-angiogenetic activity
JP4497930B2 (ja) 2002-04-23 2010-07-07 アベンティス・ファーマスーティカルズ・インコーポレイテツド インターロイキン−４遺伝子発現抑制剤としての３−置換アミノ−１Ｈ−インドール−２−カルボン酸および３−置換アミノ−ベンゾ（ｂ）チオフェン−２−カルボン酸誘導体
SE0202241D0 (sv) 2002-07-17 2002-07-17 Astrazeneca Ab Novel Compounds
MXPA05011539A (es) 2003-04-30 2006-01-23 Inst For Pharm Discovery Inc Acidos carboxilicos sustituidos con heterociclo como inhibidores de la proteina tirosina-fosfatasa-1b.
BRPI0413968A (pt) 2003-09-01 2006-10-31 Ono Pharmaceutical Co composto de anel condensado e seu uso
JP5024039B2 (ja) * 2005-02-25 2012-09-12 小野薬品工業株式会社 インドール化合物およびその用途

Also Published As

Publication number Publication date
PT2206698E (pt) 2012-08-03
CA2688614C (en) 2015-01-06
AU2009250960B2 (en) 2013-09-05
KR101464778B1 (ko) 2014-11-24
TW201026664A (en) 2010-07-16
AU2009250960A1 (en) 2010-07-08
CN101759628B (zh) 2013-02-27
TWI469965B (zh) 2015-01-21
CA2688614A1 (en) 2010-06-22
RU2505531C2 (ru) 2014-01-27
IL202869A (en) 2015-02-26
PL2206698T3 (pl) 2012-12-31
NZ582208A (en) 2011-05-27
AU2009250960C1 (en) 2014-01-23
US8115014B2 (en) 2012-02-14
JP2010168359A (ja) 2010-08-05
JP2012144546A (ja) 2012-08-02
DK2206698T3 (da) 2012-08-27
KR20100074036A (ko) 2010-07-01
ES2387185T3 (es) 2012-09-17
ZA200909096B (en) 2010-09-29
RU2009147506A (ru) 2011-06-27
BRPI0905601A2 (pt) 2012-05-02
EP2206698A1 (en) 2010-07-14
CN101759628A (zh) 2010-06-30
EP2206698B1 (en) 2012-07-18
JP5012884B2 (ja) 2012-08-29
US20100160647A1 (en) 2010-06-24

Similar Documents

Publication Publication Date Title
MX2009013926A (es) Compuestos de etinilindol.
MY154895A (en) Pyrimidine hydrazide compounds as pgds inhibitors
SG166121A1 (en) Pyrimidine amide compounds as pgds inhibitors
NZ709197A (en) 3,5-diamino-6-chloro-n-(n-(4-phenylbutyl)carbamimidoyl) pyrazine-2- carboxamide compounds
TW200708513A (en) Novel crystalline forms of tiotropium bromide
MD20140008A2 (ro) 3,5-Diamino-6-cloro-N-(N-(4-(4-(2-(hexil (2,3,4,5,6-pentahidroxihexil) amino) etoxi) fenil) butil) carbamimidoil)pirazină-2-carboxamidă
BR0107934A (pt) Carboxamidas de pirimidina úteis como inibidores de isozimas pde4
WO2008063581A3 (en) Treatment of asthma and chronic obstructive pulmonary disease with anti-proliferate and anti-inflammatory drugs
NO20074670L (no) Indolforbindelser og anvendelse derav
WO2005021515A3 (en) Inhibitors of phosphodiesterase type-iv
TW200616967A (en) Novel indazole carboxamides and their use
WO2010018109A3 (en) Substituted aminotetralines
MY159172A (en) Inhalable particles comprising tiotropium
NZ591914A (en) Naphthylacetic acids
WO2008035315A3 (en) Inhibitors of phosphodiesterase type-iv
WO2006085212A3 (en) Condensed isoxaline derivatives as inhibitors of phosphodiesterase type-iv
NZ599099A (en) Phenyloxadiazole derivatives as pgds inhibitors
NO20081480L (no) Kombinasjon av forbindelser som kan brukes ved behandling av respiratoriske sykdommer, spesielt kronisk obstruktiv pulmonaer sykdom (COPD) og astma
NO20061513L (no) Kondensert ringforbindelse og anvendelse derav
NZ709199A (en) Arylalkyl-and aryloxyalkyl-substituted epithelial sodium channel blocking compounds
NO20081483L (no) Kombinasjon av forbindelser som kan brukes ved behandling av respiratoriske sykdommer, spesielt kronisk obstruktiv pulmonaer sykdom (COPD) og astma
UA115989C2 (uk) Фармацевтична композиція для інгалятора сухого порошку, що містить антагоністи мускаринових рецепторів тривалої дії
MX2010008685A (es) Farmacoforos duales-antagonistas muscarinicos de pde4.
WO2008048560A3 (en) Toll-like receptor agonist regulation of vegf-induced tissue responses
MX2023005805A (es) Derivados de 4-aminas de (aza)quinolina como inhibidores del purinorreceptor 3 p2x (p2x3).

Legal Events

Date Code Title Description
FG Grant or registration